Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04868838 · ClinicalTrials.gov registry record · Phase 2
Daratumumab to Treat Active Lupus Nephritis
A Phase 2 study of Lupus Nephritis, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04868838 is a Phase 2 study of Lupus Nephritis that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 12 participants, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04868838, a Phase 2 study of Lupus Nephritis, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.
Conditions Studied
Interventions
- DRUG Daratumumab
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04868838
The ClinicalTrials.gov registry entry for NCT04868838 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (96% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.
NCT04868838 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04868838 about?
NCT04868838 is a clinical study titled "Daratumumab to Treat Active Lupus Nephritis". The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.
What is the current status of trial NCT04868838?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-04-20. Estimated completion is 2026-09.
What conditions does trial NCT04868838 study?
This clinical trial studies the following conditions: Lupus Nephritis.
What interventions are being tested in trial NCT04868838?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT04868838?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04868838 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
-
VIBRANT: VIB4920 for Active Lupus Nephritis
RECRUITING · Phase 2
-
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
RECRUITING · Phase 2
-
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.